Patents by Inventor Michel Dreano

Michel Dreano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8278286
    Abstract: The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: October 2, 2012
    Assignee: Merck Serono SA
    Inventors: Michel Dreano, Pierre-Alain Vitte
  • Patent number: 8003090
    Abstract: The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: August 23, 2011
    Assignee: Merck Serono SA
    Inventors: Michel Dreano, Pierre-Alain Vitte, Norman Cameron, Mary A. Cotter
  • Patent number: 7951359
    Abstract: The present invention relates to the use of IL-6 in compositions and methods for therapy or prevention of chemotherapy-induced neuropathy (CIPN). More specifically, the invention relates to the use of a low dose of IL-6 for the treatment and/or prevention CIPN.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: May 31, 2011
    Assignee: Merck Serono SA
    Inventors: Michel Dreano, Pierre-Alain Vitte
  • Patent number: 7799322
    Abstract: The invention relates to the use of IL-6 in liver cirrhosis.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: September 21, 2010
    Assignee: Merck Serono SA
    Inventors: Michel Dreano, Guido Tiberio, Gianni Garotta, Luisa Schiaffonati
  • Publication number: 20100189684
    Abstract: The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.
    Type: Application
    Filed: April 5, 2010
    Publication date: July 29, 2010
    Applicant: MERCK SERONO SA
    Inventors: Michel Dreano, Pierre-Alain Vitte
  • Publication number: 20100069316
    Abstract: The present invention provides methods of treating a subject suffering from multiple myeloma comprising administering to the subject an effect amount of a compound according to Formula I:
    Type: Application
    Filed: November 27, 2007
    Publication date: March 18, 2010
    Inventors: Michel Jourdan, Michel Dreano, Bernard Klein
  • Publication number: 20090291091
    Abstract: It is the object of the present invention to provide novel means for the treatment and/or prevention of thrombosis, tumor implantation, tumor seeding and metastasis. More specifically, the present invention relates to the use of a polypeptide comprising the globular head of Acrp30 for the manufacture of a medicament for treatment and/or prevention of thrombosis-related disorder, an hypertensive disorder of the pregnancy, tumor implantation, tumor seeding and metastasis.
    Type: Application
    Filed: June 20, 2006
    Publication date: November 26, 2009
    Applicant: Laboratoires Serono SA
    Inventors: Bernard Bihain, Michel Dreano, Jennifer Hantson, Virginie Ogier, Pierre-Alan Vitte, Frances Yen-Potin
  • Publication number: 20090169506
    Abstract: The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.
    Type: Application
    Filed: December 16, 2008
    Publication date: July 2, 2009
    Applicant: LABORATORIES SERONO SA
    Inventors: Michel DREANO, Pierre-Alain Vitte
  • Patent number: 7465441
    Abstract: The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: December 16, 2008
    Assignee: Laboratoires Serono SA
    Inventors: Michel Dreano, Pierre-Alain Vitte
  • Publication number: 20080194575
    Abstract: The present invention provides methods of treating a subject with non-alcoholic fatty liver disease (NAFLD), insulin resistance, obesity or hyperlipidemia, comprising administering to the subject an effective amount of a compound according to Formula I: or a physiologically acceptable salt thereof.
    Type: Application
    Filed: October 1, 2007
    Publication date: August 14, 2008
    Inventors: Naiara Beraza, Michel Dreano, Christian Trautwein
  • Publication number: 20080193409
    Abstract: The present invention relates to the use of IL-6 in compositions and methods for therapy or prevention of chemotherapy-induced neuropathy (CIPN). More specifically, the invention relates to the use of a low dose of IL-6 for the treatment and/or prevention CIPN.
    Type: Application
    Filed: April 28, 2005
    Publication date: August 14, 2008
    Inventors: Michel Dreano, Pierre Alain Vitte
  • Publication number: 20080107621
    Abstract: The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.
    Type: Application
    Filed: August 30, 2005
    Publication date: May 8, 2008
    Applicants: APPLIED RESEARCH SYSTEMS ARS HOLDING S.A., LABORATOIRES SERONO SA
    Inventors: Michel Dreano, Pierre-Alain Vitte, Norman Cameron, Mary A. Cotter
  • Publication number: 20080025945
    Abstract: The invention relates to the use of IL-6 in liver cirrhosis.
    Type: Application
    Filed: December 23, 2004
    Publication date: January 31, 2008
    Applicant: APPLIED RESEARCH SYSTEMS AND HOLDING N.V.
    Inventors: Michel Dreano, Guido Tiberio, Giani Garotta, Luisa Schiaffonati
  • Publication number: 20050058623
    Abstract: The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.
    Type: Application
    Filed: April 24, 2003
    Publication date: March 17, 2005
    Inventors: Michel Dreano, Pierre-Alain Vitte
  • Patent number: 6849720
    Abstract: There are provided monoclonal antibodies to the LDL receptor which are useful for the identification and purification of LDL and in treatment of e.g. hepatitis C infection.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: February 1, 2005
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Nachum Yonah, Dany Suissa, Ilana Belzer, Francesco Antonetti, Moshe Smolarsky, Michel Dreano
  • Publication number: 20030186343
    Abstract: There are provided monoclonal antibodies to the LDL receptor which are useful for the identification and purification of LDL and in treatment of e.g. hepatitis C infection.
    Type: Application
    Filed: January 15, 2003
    Publication date: October 2, 2003
    Inventors: Nachum Yonah, Dany Suissa, Ilana Belzer, Francesco Antonetti, Moshe Smolarsky, Michel Dreano
  • Patent number: 5614381
    Abstract: In the production of proteins of biological interest by means of a stress inducible gene expression unit/eukaryotic host cell system, the transformed cell lines are multiplicated by tumour growing in immunodefficient warm-blooded animals, after which the multiplicated cells are cultured in vitro and subjected to stress, whereby expression occurs in high yield. In vivo multiplication rates of 10.sup.5 -10.sup.6 the innoculated quantity/2 weeks are reported without any loss of the latent inducible expression capacity.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: March 25, 1997
    Assignee: Rothwell Properties Limited
    Inventors: Peter Bromley, Michel Dreano, Michel Fischbach, Xavier Fouillet, Prudent Padieu, Richard Voellmy